Michael E. Faerm
CIK 1647141 · Chief Financial Officer · last filed 2026-09-11
Michael E. Faerm is a Chief Financial Officer who has filed 12 SEC Form 4 insider transactions across 4 companies since 2015. The most recent filing, for ATAI, was dated Sep 11, 2026. Current disclosed insider exposure totals $5.9M across reported positions. 10 SEC filings were submitted jointly with Innoviva, Inc.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
INVA price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
250 WEST 34TH STREET
NEW YORK, NY 10119
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| AtaiBeckley Inc. (ATAI) Delisted | Chief Financial Officer | — | $7.35 | — | $0 | 1 | 2026-09-11 |
| Viracta Therapeutics, Inc. (VIRX) Delisted | Chief Financial Officer | — | $0.01 | — | $0 | 1 | 2024-05-16 |
| INVA | Sr VP & Chief Business Officer | 279,422 | $21.05 | $5.88M | $0 | 8 | 2017-11-22 |
| Innoviva, Inc. (THRX) Delisted | Sr VP & Chief Business Officer | 105,288 | $4.06 | $427.5K | $0 | 1 | 2015-07-27 |
Recent Filings
12 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-09-11 | AtaiBeckley Inc. (ATAI) Delisted | Disp (D) | — | $0 | EDGAR |
| 2026-03-13 | — | Grant (A) | — | $0 | |
| 2024-05-16 | Viracta Therapeutics, Inc. (VIRX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-11-22 | INVA | Tax (F) | −4,470 | -$58.9K | EDGAR |
| 2017-08-22 | INVA | Tax (F) | −3,179 | -$39.0K | EDGAR |
| 2017-05-23 | INVA | Tax (F) | −3,176 | -$37.7K | EDGAR |
| 2017-02-22 | INVA | Tax (F) | −5,860 | -$70.6K | EDGAR |
| 2017-01-19 | INVA | Grant (A) | +133,398 | $0 | EDGAR |
| 2016-11-22 | INVA | Tax (F) | −2,893 | -$31.6K | EDGAR |
| 2016-08-23 | INVA | Tax (F) | −9,544 | -$112.5K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.